Golazo device for removing plaque in leg artery disease
Tests the Golazo atherectomy device in 159 people with leg peripheral arterial disease.
Key facts
- Who runs it
- Nipro Vascular Innovations Americas, Inc
- Where
- ‘Aiea, Baton Rouge, Beaumont, Flemington, Fort Lauderdale, Green Bay, Houma, Houston, Jacksonville, Lafayette, Lakeland, Merced, Miami, Plymouth, Scottsdale, Spartanburg, Thomasville, Tullahoma, and Waco, United StatesSee the 20 sites
- Trial code
- Registry title
- The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- Status
- Recruiting
- People taking part
- 159 people, planned
- Started
- 20 Jun 2024
- Expected to end
- Nov 2026
- Type of study
- Interventional
- Treatments tested
- Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS)
- Record updated
- 27 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with narrowed leg arteries below the groin (peripheral arterial disease) that cause symptoms. They need a procedure to remove plaque from the artery (atherectomy).
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Rutherford category 3 to 5 in the leg to be treated. Narrowing of 70% or more. Total treated length 20 cm (7.9 in) or less. Vessel size 2.0 mm to 4.5 mm. At least one open artery below the knee must reach the foot. Life expectancy more than 1 year.
- Earlier treatment
- No artery procedure or open artery surgery on the treated leg in the last 30 days. No clot-dissolving treatment within two weeks before joining.
- Biomarker or test result
- Resting ankle brachial index (ABI) of 0.90 or less, or 0.75 or less after exercise. People with stiff arteries that cannot be pressed need a toe brachial index (TBI) test.
Main reasons for not taking part
- Rutherford category 6 (most severe limb ischemia) or serious foot wounds, gangrene or bone infection
- Serious kidney disease with GFR <30 or needing dialysis
- Heart attack or stroke within two months, or heart failure NYHA class III or higher
- Bleeding problems, platelet count <125,000/microliter, INR >1.5, or past brain or gut bleeding
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 40 criteriaShow less
Other criteria
- General inclusion criteria:
- Age ≥18 years
- Candidate for atherectomy of the peripheral vasculature in the lower limbs
- Life expectancy >1 year in the opinion of the investigator
- Resting ankle brachial index (ABI) ≤0.90, or ≤0.75 after exercise. Subjects with non-compressible arteries shall have a toe brachial index (TBI) assessment
- Target limb Rutherford clinical classification category 3 to 5
- Suitable candidate for angiography and endovascular intervention in the opinion of the investigator
- Willing and able to comply with the protocol-specified procedures and assessments
- Informed consent granted; Angiographic inclusion criteria:
- Target lesion(s) defined as stenosis ≥70% by angiographic visual estimation
- Total treated lesion length ≤20 cm by angiographic visual estimation
- Target reference vessel diameter (RVD) ≥2.0 mm and ≤4.5 mm by angiographic visual estimation
- Target limb will have a minimum of one patent (less than 50% stenosis) below the knee (BTK) vessel crossing the ankle, distal to any target lesion, providing perfusion to the foot at baseline; General exclusion criteria:
- Active infection in the target limb
- History of an endovascular procedure or open vascular surgery on the target limb within the last 30 days
- Planned surgical or interventional procedure within 30 days after the index procedure
- Lesion in the contralateral limb requiring intervention during the index procedure or within next 30 days
- Critical limb ischemia (CLI) with Rutherford clinical classification category 6
- Significant acute or chronic kidney disease with a GFR <30 and/or requiring dialysis
- Acute myocardial infarction (non-ST-elevation myocardial infarction or ST-segment elevation myocardial infarction) or other uncontrolled comorbidity in the opinion of the investigator
- Myocardial infarction (MI) or stroke within two months of baseline evaluation
- Pregnant or lactating
- Subject is participating in another clinical investigation of a device, drug, or procedure that has not completed the study treatment or that clinically interferes with the endpoints of this study (post-approval registries are allowed as long as the investigator determines there is no clinical interference with study endpoints)
- Contraindication to antiplatelet, anticoagulant, or thrombolytic therapy
- Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count <125,000/microliter, known coagulopathy, or international normalized ratio (INR) >1.5
- Known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately medicated
- History of heparin-induced thrombocytopenia (HIT)
- Any thrombolytic therapy within two weeks of enrollment
- Target lesion(s) within a native vessel graft or synthetic graft
- Significant stenosis or occlusion of inflow not successfully treated before the index procedure
- Any evidence or history of intracranial or gastrointestinal bleeding or intracranial aneurysm
- Vulnerable subject populations (e.g., incarcerated or cognitively challenged adults)
- One or more of the following complications of the foot:; Osteomyelitis that extends to the metatarsal bones; Gangrene involving the plantar skin of the forefoot, midfoot or heel; Deep ulcer or large shallow ulcer (>3cm) involving the plantar skin of the forefoot, midfoot, or heel; Any heel ulcer with/without calcaneal involvement; Any wound with calcaneal bone involvement; Wounds that are deemed to be neuropathic or non-ischemic in nature; Wounds that require flap coverage or complete wound management for large soft tissue defect
- Congestive heart failure with a NYHA functional classification of III or higher; Angiographic exclusion criteria:
- More than 2 lesions to be treated with the investigational device; lesions located within 3 mm may be considered a single tandem lesion
- Clinical/angiographic complication (other than non-flow limiting dissections) attributed to a currently marketed device prior to introduction of the investigational device
- In-stent restenosis within the target lesion(s)
- Potentially unstable or flow-limiting dissection, type C or greater
- Clinical/angiographic evidence of distal embolization
- Inability to cross the proximal lesion vessel lumen with a guidewire (not subintimal)
Where in United States
- Pacific Vascular Institute‘Aiea, United StatesContact: Amber ParrillaTaking people
- Baton Rouge General HospitalBaton Rouge, United StatesContact: Jamie MooneyTaking people
- Nextstage Clinical Research - BeaumontBeaumont, United StatesContact: Jorge Hernandez, MD (principal investigator)Taking people
- Advanced Heart and Vascular InstituteFlemington, United StatesContact: Alexis BellafioreTaking people
- Palm Vascular CenterFort Lauderdale, United StatesContact: Jennifer GimenoTaking people
- Bellin HealthGreen Bay, United StatesContact: Katherine GuilliamsTaking people
- Cardiovascular Institute of the South - HoumaHouma, United StatesContact: Deanna BenoitTaking people
- Hope Vascular & PodiatryHouston, United StatesContact: Miguel Montero-BackerTaking people
- First Coast Cardiovascular InstituteJacksonville, United StatesContact: Amy SuphachindaTaking people
- Cardiovascular Institute of the South - LafayetteLafayette, United StatesContact: Nichol CharlesTaking people
- Radiology and Imaging Specialists of LakelandLakeland, United StatesContact: Gene ReuNo longer taking part
- Merced VascularMerced, United StatesContact: Mani Nallasivan, MD (principal investigator)Taking people
- Amavita Research ServicesMiami, United StatesContact: Nereisy AlonsoTaking people
- Vascular BreakthroughsPlymouth, United StatesContact: Elizabeth GagneTaking people
- Pulse Cardiovascular InstituteScottsdale, United StatesContact: Anita Ramaiah, MDTaking people
- HonorHealth Scottsdale Osborn Medical CenterScottsdale, United StatesContact: Gene ReuNo longer taking part
- Spartanburg Regional Medical CenterSpartanburg, United StatesContact: Darla Howard, RNTaking people
- Cardiovascular Consultants of South GeorgiaThomasville, United StatesContact: Gene ReuNo longer taking part
- Tennessee Center for Clinical TrialsTullahoma, United StatesContact: Dinesh Gupta, MD (principal investigator)Taking people
- NextStage Clinical Research - WacoWaco, United StatesContact: Donald S Cross, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
The objective of this study is to establish reasonable assurance of safety and effectiveness of the Golazo® Peripheral Atherectomy System when used as indicated in 159 subjects with symptomatic infrainguinal peripheral arterial disease (PAD) in up to 20 investigational sites in the U.S.
The group in the trial
- Golazo® Peripheral Atherectomy SystemTreatment being tested
Treatment atherectomy of the peripheral vasculature with the Golazo® Peripheral Atherectomy System.
Treatment: Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy
- Plain-language title
- Golazo device for removing plaque in leg artery diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 27 August 2026